S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
BREAKING: Tiny biotech successfully treats blindness (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Investing Legend Warns: NVIDIA is a "Delusion" (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Investing Legend Warns: NVIDIA is a "Delusion" (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
BREAKING: Tiny biotech successfully treats blindness (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Investing Legend Warns: NVIDIA is a "Delusion" (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Investing Legend Warns: NVIDIA is a "Delusion" (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
BREAKING: Tiny biotech successfully treats blindness (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Investing Legend Warns: NVIDIA is a "Delusion" (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Investing Legend Warns: NVIDIA is a "Delusion" (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
BREAKING: Tiny biotech successfully treats blindness (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Investing Legend Warns: NVIDIA is a "Delusion" (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Investing Legend Warns: NVIDIA is a "Delusion" (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford

Rain Oncology (RAIN) Stock Forecast, Price & News

$0.85
0.00 (0.00%)
(As of 09/22/2023 ET)
Compare
Today's Range
$0.84
$0.88
50-Day Range
$0.82
$1.42
52-Week Range
$0.82
$14.48
Volume
99,679 shs
Average Volume
143,795 shs
Market Capitalization
$30.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00

Rain Oncology MarketRank™ Forecast

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
1,910.4% Upside
$17.00 Price Target
Short Interest
Healthy
4.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.73mentions of Rain Oncology in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.67) to ($0.72) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

311th out of 963 stocks

Pharmaceutical Preparations Industry

132nd out of 458 stocks


RAIN stock logo

About Rain Oncology (NASDAQ:RAIN) Stock

Rain Oncology Inc., a late-stage precision oncology company, engages in developing therapies that target oncogenic drivers to genetically select patients in the United States. The company's lead product candidate is milademetan, a small molecule oral inhibitor of MDM2-p53 complex that reactivates p53. The company was formerly known as Rain Therapeutics Inc. and changed its name to Rain Oncology Inc. in December 2022. Rain Oncology Inc. was incorporated in 2017 and is headquartered in Newark, California.

RAIN Price History

RAIN Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
See More Headlines
Receive RAIN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rain Oncology and its competitors with MarketBeat's FREE daily newsletter.

RAIN Company Calendar

Last Earnings
8/10/2023
Today
9/24/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RAIN
Fax
N/A
Employees
63
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.00
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+1,910.4%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
12 Analysts

Profitability

Net Income
$-75,720,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.11 per share

Miscellaneous

Free Float
30,047,000
Market Cap
$30.76 million
Optionable
Not Optionable
Beta
0.21

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Avanish Vellanki M.B.A. (Age 48)
    Co-Founder, CEO & Chairman
    Comp: $959.75k
  • Dr. Robert C. Doebele M.D. (Age 52)
    Ph.D., Co-Founder, Chairman of Scientific Advisory Board, Pres & CSO and Chief Medical Officer
    Comp: $700.56k
  • Ms. Josephine Bruce (Age 44)
    Principal Financial & Accounting officer
  • Ms. Theresa O'Connell M.S.
    Director of Corp. Devel. & Operations
  • Mr. Erik Atkisson (Age 51)
    Gen. Counsel & Chief Compliance Officer
  • Ms. Charmi Turner
    VP of People & Culture
  • Ms. Vijaya Tirunagaru Ph.D.
    Sr. VP & Head of Research
  • Dr. Nora Ku M.D.
    MD & VP of Clinical Devel.













RAIN Stock - Frequently Asked Questions

Should I buy or sell Rain Oncology stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rain Oncology in the last twelve months. There are currently 10 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" RAIN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RAIN, but not buy additional shares or sell existing shares.
View RAIN analyst ratings
or view top-rated stocks.

What is Rain Oncology's stock price forecast for 2023?

12 analysts have issued twelve-month price targets for Rain Oncology's stock. Their RAIN share price forecasts range from $11.00 to $24.00. On average, they anticipate the company's share price to reach $17.00 in the next twelve months. This suggests a possible upside of 1,910.4% from the stock's current price.
View analysts price targets for RAIN
or view top-rated stocks among Wall Street analysts.

How have RAIN shares performed in 2023?

Rain Oncology's stock was trading at $8.00 on January 1st, 2023. Since then, RAIN shares have decreased by 89.4% and is now trading at $0.8456.
View the best growth stocks for 2023 here
.

Are investors shorting Rain Oncology?

Rain Oncology saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 861,800 shares, a decline of 20.2% from the August 15th total of 1,080,000 shares. Based on an average trading volume of 472,700 shares, the days-to-cover ratio is currently 1.8 days. Currently, 4.3% of the company's shares are sold short.
View Rain Oncology's Short Interest
.

When is Rain Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our RAIN earnings forecast
.

How were Rain Oncology's earnings last quarter?

Rain Oncology Inc. (NASDAQ:RAIN) announced its quarterly earnings results on Thursday, August, 10th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.12.

What ETFs hold Rain Oncology's stock?

ETFs with the largest weight of Rain Oncology (NASDAQ:RAIN) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), Horizon Kinetics Medical ETF (MEDX),

When did Rain Oncology IPO?

(RAIN) raised $126 million in an initial public offering on Friday, April 23rd 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Goldman Sachs, Citigroup, Piper Sandler and Guggenheim Securities acted as the underwriters for the IPO.

What is Rain Oncology's stock symbol?

Rain Oncology trades on the NASDAQ under the ticker symbol "RAIN."

Who are Rain Oncology's major shareholders?

Rain Oncology's stock is owned by many different institutional and retail investors. Top institutional shareholders include Samsara BioCapital LLC (5.60%), Boxer Capital LLC (3.17%), BlackRock Inc. (2.80%), Acadian Asset Management LLC (1.81%), Western Standard LLC (0.95%) and Geode Capital Management LLC (0.89%). Insiders that own company stock include Aaron I Davis, Boxer Capital, Llc, Bvf Partners L P/Il, Cormorant Asset Management, Lp, Franklin M Berger, Kevin C Tang, Perceptive Advisors Llc and Value Fund L P Biotechnology.
View institutional ownership trends
.

How do I buy shares of Rain Oncology?

Shares of RAIN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rain Oncology's stock price today?

One share of RAIN stock can currently be purchased for approximately $0.85.

How much money does Rain Oncology make?

Rain Oncology (NASDAQ:RAIN) has a market capitalization of $30.76 million. The company earns $-75,720,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis.

How can I contact Rain Oncology?

The official website for the company is www.rainthera.com. The company can be reached via phone at 510-953-5559 or via email at bob@lifesciadvisors.com.

This page (NASDAQ:RAIN) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -